Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease

Lee, Bor‐Jen; Huang, Yann-Chang; Chen, Shu-Ju; Lin, Ping-Ting

doi:10.1016/j.nut.2011.11.008

Cited by 79 publications

(58 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though the commercial formulation used in this study is reported to exhibit improved peroral bioavailability (Chopra, 2001), it is just not enough in the system under the current dosage regimen to elicit any positive response, may be a daily dosing would have been better with commercial form. Even though a precise mechanism of action of CoQ 10 in MI is not known, in general it is attributed to its 13 antioxidant nature, ability to minimize inflammation, improve endothelium function (Dai et al, 2011;Lee et al, 2012). We have previously reported the efficacy of CoQNPs in other experimental models (Ankola et al, 2007;Ratnam et al, 2009) however a more systematic understanding is required on their therapeutic potential before much efforts are put in to prove the performance of these compounds that are in general high dose molecules and currently in use as supplements.…”

Section: Coq 10 Loaded Nanoparticle Efficacy Studymentioning

confidence: 99%

Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Simón-Yarza

Tamayo

Benavides

et al. 2013

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Myocardial ischemia (MI) remains one of the leading causes of death worldwide.Angiogenic therapy with the vascular endothelial growth factor (VEGF) is a promising strategy to overcome hypoxia and its consequences. However, from the clinical data it is clear that fulfillment of the potential of VEGF warrants a better delivery strategy. On the other hand, the compelling evidences of the role of oxidative stress in diseases like MI encourage the use of antioxidant agents. Coenzyme Q 10 (CoQ 10 ) due to its role in the electron transport chain in the mitochondria seems to be a good candidate to manage MI but is associated with poor biopharmaceutical properties seeking better delivery approaches.The female Sprague Dawley rats were induced MI and were followed up with VEGF microparticles intramyocardially and CoQ 10 nanoparticles orally or their combination with appropriate controls. Cardiac function was assessed by measuring ejection fraction before and after three months of therapy.Results demonstrate significant improvement in the ejection fraction after three months with both treatment forms individually; however the combination therapy failed to offer any synergism. In conclusion, VEGF microparticles and CoQ 10 nanoparticles can be considered as promising strategies for managing MI.

show abstract

Section: Coq 10 Loaded Nanoparticle Efficacy Studymentioning

confidence: 99%

Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Simón-Yarza

Tamayo

Benavides

et al. 2013

International Journal of Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Thus far, it has been established that CoQ 10 delivers therapeutic benefits in some heart conditions, including heart failure and coronary artery disease (Lee et al, 2012a(Lee et al, , 2012bLittarru and Tiano, 2010;Singh et al, 1998;Smith and Murphy, 2010). A human clinical study investigating the relation between CoQ 10 and inflammation in patients with coronary artery disease reports that oral supplementation of CoQ 10 at 150 mg/day results in decreased expression of inflammatory markers, that is, C-reactive protein, IL-6, and homocysteine (Lee et al, 2012b).…”

Section: Introductionmentioning

confidence: 99%

“…A human clinical study investigating the relation between CoQ 10 and inflammation in patients with coronary artery disease reports that oral supplementation of CoQ 10 at 150 mg/day results in decreased expression of inflammatory markers, that is, C-reactive protein, IL-6, and homocysteine (Lee et al, 2012b). Furthermore, data collected from human and rodent cellular models show that CoQ 10 affects gene expression and inhibits the release of IL-6 and TNF-α, consistent with its anti-inflammatory effects (Schmelzer et al, 2007(Schmelzer et al, , 2008.…”

Section: Introductionmentioning

confidence: 99%

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Sikorska

Lanthier

Miller

et al. 2014

Neurobiology of Aging

View full text Add to dashboard Cite

Although the support for the use of antioxidants, such as coenzyme Q 10 (CoQ 10 ), to treat Parkinson's disease (PD) comes from the extensive scientific evidence, the results of conducted thus far clinical trials are inconclusive. It is assumed that the efficacy of CoQ 10 is hindered by insolubility, poor bioavailability, and lack of brain penetration. We have developed a nanomicellar formulation of CoQ 10 (Ubisol-Q 10 ) with improved properties, including the brain penetration, and tested its effectiveness in mouse MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) model with the objectives to assess its potential use as an adjuvant therapy for PD. We used a subchronic MPTP model (5-daily MPTP injections), characterized by 50% loss of dopamine neurons over a period of 28 days. Ubisol-Q 10 was delivered in drinking water. Prophylactic application of Ubisol-Q 10 , started 2 weeks before the MPTP exposure, significantly offset the neurotoxicity (approximately 50% neurons died in MPTP group vs. 17% in MPTP+ Ubisol-Q 10 group by day 28). Therapeutic application of Ubisol-Q 10 , given after the last MPTP injection, was equally effective. At the time of intervention on day 5 nearly 25% of dopamine neurons were already lost, but the treatment saved the remaining 25% of cells, which otherwise would have died by day 28. This was confirmed by cell counts, analyses of striatal dopamine levels, and improved animals' motor skill on a beam walk test. Similar levels of neuroprotection were obtained with 3 different Ubisol-Q 10 concentrations tested, that is, 30 mg, 6 mg, or 3 mg CoQ 10 /kg body weight/day, showing clearly that high doses of CoQ 10 were not required to deliver these effects. Furthermore, the Ubisol-Q 10 treatments brought about a robust astrocytic activation in the brain parenchyma, indicating that astroglia played an active role in this neuroprotection. Thus, we have shown for the first time that Ubisol-Q 10 was capable of halting the neurodegeneration already in progress;

show abstract

“…The results revealed that supplementation with Q10 plus LC significantly reduced hs-CRP and IL-6 levels. In contrast, some studies disclosed a 14% decrease in IL-6 levels after supplementation with Q10 150 mg/d, and no significant change in hs-CRP levels (22). Previous studies also showed that IL-6 and CRP levels decreased significantly after LC supplementation (1000 mg/d) in patients with coronary artery disease (21).…”

Section: The Effect Of Q10 Plus Lc Supplementationmentioning

confidence: 95%

“…There are conflicting research results about the effects of Q10 and LC on inflammatory markers (21)(22)(23), lipid profiles (24,25), and LVEF (26,27). Although coenzyme Q10 supplementation has been found to affect inflammatory markers in healthy subjects, few clinical studies have investigated the relation between coenzyme Q10 and inflammation in patients with MI.…”

Section: Introductionmentioning

confidence: 99%

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Sharifi

Eftekhari

Ostovan

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Following Myocardial Infarction (MI) and percutaneous coronary intervention (PCI), the modification of cardiovascular risk factors and inflammation can improve MI progression and PCI outcomes. Up to now, no certain conclusions have been drawn regarding the effect of therapeutic lifestyle change (TLC) diet and a combination of Q10 plus L-carnitine (LC) supplementation on inflammatory biomarkers of In-Stent Restenosis (ISR), lipid profile, and Left ventricular ejection fraction (LVEF).Objectives: This study aimed to evaluate the effects of TLC diet and Q10 plus LC supplementation on inflammatory biomarkers of ISR, lipid profile, and LVEF following MI and PCI.Methods: This single-blind randomized controlled trial was conducted on 128 subjects. After randomization for treatment allocation, the subjects were divided into the study groups through block randomization. The MI patients were admitted to 2 hospitals, namely Al-Zahra and Kowsar (Shiraz, Iran), between April 2015 and May 2016. The patients were divided into 4 groups receiving TLC diet (A), oral Q10 150 mg/d and LC 1200 mg/d (B), a combination of LC plus Q10 and TLC diet (C), and the routine care (D). This study evaluated Interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP) as inflammatory biomarkers of ISR, lipid profile, and LVEF in 128 patients with MI undergoing PCI before and 3 months after the intervention. Results:The results showed a significant decrease in hs-CRP in groups B (11.8 ± 4.3 to 2.0 ± 1 mg/L) and C (11.7±3.9 to 1.3±1.1 mg/L) (P < 0.0001 and P < 0.0001, respectively), but not in group A. Also, a significant reduction was found in IL-6 in groups A (38.0 ± 15 to 9.4 ± 2 pg/mL), B (34.6 ± 12 to 5.1 ± 2.4 pg/mL), and C (33.7 ± 12 to 4.8 ± 2.1 pg/mL) (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). Additionally, LDL and total cholesterol, but not TG, levels significantly decreased in groups A (150 ± 17 to 80 ± 13 mg/dL), B (148 ± 15 to 77.2 ± 14 mg/dL), and C (142 ± 11 to 64.8 ± 10 mg/dL) (P < 0.0001, P < 0.001, and P < 0.0001, respectively). Nevertheless, only group C showed a significant improvement in LVEF (45.1 ± 8 to 53.6 ± 8) (P < 0.027).Conclusions: An adjuvant therapy with TLC diet and supplementation with Q10 and LC seems to be required for secondary prevention following MI and PCI. TLC diet and Q10 plus LC appeared to be effective in inflammatory biomarkers of ISR as well as LDL reduction.

show abstract

Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease

Cited by 79 publications

References 34 publications

Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Contact Info

Product

Resources

About